resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs. placebo. However, based on a prespecified pooled analysis of the trial's Parts 1 and 2

Read the full 503 word article

User Sign In